BOT

BOTANIX PHARMACEUTICALS LTD

2.50%

2.1¢

Market Cap $54.68M

Healthcare

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Latest Threads

Tag

Subject

BOT

Ann: Appendix 4C - quarterly

24/04/18

1.5K

24/04/18

Last post Jalaluddin

1.5K

BOT

Positive for BOT

2 3

15:48

147

43K

15:48

Last post Lacan

147

43K

BOT

Vote by proxy

19/04/18

4.1K

19/04/18

Last post bluey10

4.1K

BOT Medicine

Update on dermatutis study

17/04/18

1.0K

17/04/18

Last post NZ Trader

1.0K

BOT

Ann: Notice of General Meeting/Proxy Form

12/04/18

2.3K

12/04/18

Last post NZ Trader

2.3K

BOT

Ann: Investor Presentation

11/04/18

7.6K

11/04/18

Last post aburbe

7.6K

BOT

Ann: Enrolment of BTX 1204 Atopic Dermatitis Study Completed

09/04/18

4.6K

09/04/18

Last post aburbe

4.6K

BOT

The Comeback!!!!

22/03/18

32K

22/03/18

Last post beefarmer

32K

See All Discussions

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.


Last 2.1¢		Change 0.001(2.50%)		Mkt cap ! $54.68M

Open	High	Low	Volume
2.1¢	2.1¢	2.0¢	1.818M

Buyers (Bids)

Vol.	Price($)
12392431	2.0¢

Sellers (Offers)

Price($)	Vol.
2.1¢	6508155

Last trade - 16.10pm 21/08/2026 (20 minute delay)

BOT (ASX) Chart

BOTANIX PHARMACEUTICALS LTD

Corporate Spotlight
Not Yet Available

Latest Threads

Featured News

Latest Articles

Last year's anti-sweat biotech darling Botanix falls -10% on poorly received quarterly

Botanix Pharma (ASX:BOT) saw its share price fall around -10% on Tuesday as the company’s latest quarterly update, in which sales of its anti-chronic-sweating drug Sofdra are in the spotlight, failed to impress investors (who are likely, in Botanix’s defence, payin...

Botanix jumps back above 15cps on '65%' revenue growth to $7M; new sales force boost

Botanix latest quarterly earnings report showed that revenues from anti-sweating drug Sofdra have increased to $7.1 million.

Maybe sweat the small stuff: Botanix underwhelms, falls -40%

The problem with building big valuation expectations on the treatment of rare diseases is that you either need expensive drugs, or, some kind of government support, because a rare disease, by its very nature, implies a small addressable market.Listen to the HotCopper podcast for in-depth discussi...

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News

BOTANIX PHARMACEUTICALS LTD

Corporate SpotlightNot Yet Available

Latest Threads

Featured News

Latest Articles

Last year's anti-sweat biotech darling Botanix falls -10% on poorly received quarterly

Botanix Pharma (ASX:BOT) saw its share price fall around -10% on Tuesday as the company’s latest quarterly update, in which sales of its anti-chronic-sweating drug Sofdra are in the spotlight, failed to impress investors (who are likely, in Botanix’s defence, payin...

Botanix jumps back above 15cps on '65%' revenue growth to $7M; new sales force boost

Botanix latest quarterly earnings report showed that revenues from anti-sweating drug Sofdra have increased to $7.1 million.

Maybe sweat the small stuff: Botanix underwhelms, falls -40%

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News

Corporate Spotlight
Not Yet Available